Tepmetko Alternatives Compared
Tepmetko | Rybrevant | Tagrisso |
|
---|
Tepmetko (tepotinib) | Rybrevant (amivantamab) | Tagrisso (osimertinib) |
|
|||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Prescription only
Prescribed for Non Small Cell Lung Cancer. Tepmetko may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Non Small Cell Lung Cancer. Rybrevant may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Non Small Cell Lung Cancer. Tagrisso may also be used for purposes not listed in this medication guide. |
||||||||||||||||||||||||
More about Tepmetko (tepotinib) | More about Rybrevant (amivantamab) | More about Tagrisso (osimertinib) | ||||||||||||||||||||||||
Ratings & Reviews | ||||||||||||||||||||||||||
Be the first to share your experience with this drug. |
Rybrevant has an average rating of 9.0 out of 10 from a total of 2 ratings on Drugs.com. 100% of reviewers reported a positive effect, while 0% reported a negative effect. |
Tagrisso has an average rating of 7.3 out of 10 from a total of 37 ratings on Drugs.com. 65% of reviewers reported a positive effect, while 24% reported a negative effect. |
||||||||||||||||||||||||
Drug Class | ||||||||||||||||||||||||||
Side Effects | ||||||||||||||||||||||||||
See also: Tepmetko side effects in more detail. |
See also: Rybrevant side effects in more detail. |
See also: Tagrisso side effects in more detail. |
||||||||||||||||||||||||
Generic Availability | ||||||||||||||||||||||||||
N/A |
||||||||||||||||||||||||||
Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Tepmetko prices |
View all Rybrevant prices |
View all Tagrisso prices |
||||||||||||||||||||||||
Dosage Forms Available | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
Brand Names | ||||||||||||||||||||||||||
N/A |
N/A |
N/A |
||||||||||||||||||||||||
Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | ||||||||||||||||||||||||||
N/A |
271.2 hours |
48 hours |
||||||||||||||||||||||||
CSA Schedule ** View glossary of terms | ||||||||||||||||||||||||||
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
Pregnancy Category | ||||||||||||||||||||||||||
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||||||||||||||||||
Drug Interactions | ||||||||||||||||||||||||||
A total of 264 drugs are known to interact with Tepmetko:
|
A total of 3 drugs are known to interact with Rybrevant:
|
A total of 580 drugs are known to interact with Tagrisso:
|
||||||||||||||||||||||||
Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||
Disease Interactions | ||||||||||||||||||||||||||
First Approval Date | ||||||||||||||||||||||||||
February 03, 2021 |
May 21, 2021 |
November 13, 2015 |
||||||||||||||||||||||||
WADA Class View World Anti-Doping Agency classifications. | ||||||||||||||||||||||||||
N/A |
N/A |
N/A |
||||||||||||||||||||||||
More Information | ||||||||||||||||||||||||||
Patient resources | ||||||||||||||||||||||||||
Professional Resources | ||||||||||||||||||||||||||
Related Treatment Guide | ||||||||||||||||||||||||||
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.